Abstract
Treatment with second-generation antipsychotics (SGAs) has been associated with weight gain and the development of diabetes mellitus, although the mechanisms are unknown. We tested the hypothesis that SGAs exert direct cellular effects on insulin action and substrate metabolism in adipocytes. We utilized two cultured cell models including 3T3-L1 adipocytes and primary cultured rat adipocytes, and tested for effects of SGAs risperidone (RISP), clozapine (CLZ), olanzapine (OLZ), and quetiapine (QUE), together with conventional antipsychotic drugs butyrophenone (BUTY), and trifluoperazine (TFP), over a wide concentration range from 1 to 500 μM. The effects of antipsychotic drugs on basal and insulin-stimulated rates of glucose transport were studied at 3 h, 15 h, and 3 days. Both CLZ and OLZ (but not RISP) at doses as low as 5 μM were able to significantly decrease the maximal insulin-stimulated glucose transport rate by ∼40% in 3T3-L1 cells, whereas CLZ and RISP reduced insulin-stimulated glucose transport rates in primary cultured rat adipocytes by ∼50–70%. Conventional drugs (BUTY and TFP) did not affect glucose transport rates. Regarding intracellular glucose metabolism, both SGAs (OLZ, QUE, RISP) and conventional drugs (BUTY and TFP) increased basal and/or insulin-stimulated glucose oxidation rates, whereas rates of lipogenesis were increased by CLZ, OLZ, QUE, and BUTY. Finally, rates of lipolysis in response to isoproterenol were reduced by the SGAs (CLZ, OLZ, QUE, RISP), but not by BUTY or TFP. These experiments demonstrate that antipsychotic drugs can differentially affect insulin action and metabolism through direct cellular effects in adipocytes. However, only SGAs were able to impair the insulin-responsive glucose transport system and to impair lipolysis in adipocytes. Thus, SGAs directly induce insulin resistance and alter lipogenesis and lipolysis in favor of progressive lipid accumulation and adipocyte enlargement. These effects of SGAs on adipocytes could explain, in part, the association of SGAs with weight gain and diabetes.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ader M, Garvey WT, Phillips LS, Nemeroff CB, Weinberger DR, Gharabawi G et al (2005). Glucoregulation and adiposity with antipsychotic therapy in schizophrenia. National meeting of the American Psychiatric Association, Abstract NR828 (published online at: http://www.psych.org/edu/other_res/lib_archives/archives/meetings/2005nra.cfm).
Ananth J, Kolli S (2005). Atypical antipsychotic agents and increased risk of diabetes: class action or differential action? Expert Opin Drug Saf 4: 55–68.
Ananth J, Venkatesh R, Burgoyne K, Gunatilake S (2002). Atypical antipsychotic drug use and diabetes. Psychother Psychosom 71: 244–254.
Aravagiri M, Marder SR, Yuwiler A, Midha KK, Kula NS, Baldessarini RJ (1995). Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 13: 235–247.
Aravagiri M, Yuwiler A, Marder SR (1998). Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 139: 356–363.
Aravagiri M, Teper Y, Marder SR (1999). Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20: 369–377.
Ardizzone TD, Bradley RJ, Freeman AM, Dwyer DS (2001). Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 923: 82–90.
Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993). Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9: 117–124.
Bergman RN, Ader M (2005). Atypical antipsychotics and glucose homeostasis. J Clin Psychiat 66: 504–514.
Bridler R, Umbricht D (2003). Atypical antipsychotic in treatment of schizophrenia. Swiss Med Wkly 133: 63–73.
Broich K, Heinrich S, Marneros A (1998). Acute clozapine overdose: plasma concentration and outcome. Pharmacopsychiatry 31: 149–151.
Burns MJ (2001). The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol 39: 1–14.
Casey DE (2005). Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 118: 15–22.
Cohen D (2004). Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 37: 1–11.
Davidson M (2002). Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiat 63: 5–11; erratum in J Clin Psychiatry 63: 744.
Digirolamo M, Medlinger S, Fertig JW (1971). A simple method to determine cell size and number in four mammalian species. Am J Physiol 221: 850.
Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM (2001). Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psych 13: 103–113.
Gardiner TH, Lewis JM, Shore PA (1978). Distribution of clozapine in the rat: localization in lung. J Pharmacol Exp Ther 206: 151–157.
Garvey WT, Olefsky JM, Marshall S (1985). Insulin induces insulin resistance in cultured rat adipocytes: sequential effects at receptor and multiple postreceptor sites. Diabetes 35: 258–267.
Garvey WT, Olefsky JM, Matthaei S, Marshall S (1987). Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes: a new mechanism of insulin resistance. J Biol Chem 262: 189–197.
Garvin PR, Zhang ZJ, Zhang XB (2002). Association of antipsychotic drug-induced weight gain with a 5-5-HT2C receptor gene polymorphism. Lancet 359: 2086–2087.
Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T (2001). Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiat 62: 843–848.
Harvey PD, Bowie CR (2005). Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Expert Opin Pharmacother 6: 337–346.
Hunter SJ, Garvey WT (1998). Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 105: 331–345.
Kapur S, Remington G (2001). Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiat 50: 873–883.
Kaur G, Kulkarni SK (2002). Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiat 26: 277–285.
Lean ME, Pajonk FG (2003). Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26: 1597–1605.
Lebovitz HE (2003). Metabolic consequences of atypical antipsychotic drugs. Psychiatr Quart 74: 277–290.
Lima FB, Bao S, Garvey WT (1994). Biologic actions of insulin are differentially regulated by glucose and insulin in primary cultured adipocytes: chronic ability to increase glycogen synthase activity. Diabetes 43: 53–62.
Mayor P, Maianu L, Garvey WT (1992). Glucose and insulin chronically regulate insulin action via different mechanisms in BC3H1 myocytes: effects on glucose transporter gene expression. Diabetes 41: 274–285.
Newcomer JW (2005a). Clinical considerations in selecting and using atypical antipsychotics. CNS Spectr 10: 12–20.
Newcomer JW (2005b). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19: 1–93.
Nonogaki K (2000). New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43: 533–549.
Reynolds GP (2004). Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18: 340–345.
Robinson KA, Yacoub Wasef SZ, Buse MG (2006). At therapeutic concentrations, olanzapine does not affect basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes. Prog Neuropsychopharmacol Biol Psychiat 30: 93–98.
Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF et al (1995). Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374: 542–546.
Tsuneizumi T, Babb SM, Cohen BM (1992). Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiat 32: 817–824.
Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiat 184: 58–62.
Acknowledgements
This work was funded by an investigator-initiated research grant from Janssen Pharmaceutica Inc. Additional support was obtained from the National Institutes of Health (DK-38765) and the Merit Review program of the Department of Veterans Affairs.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vestri, H., Maianu, L., Moellering, D. et al. Atypical Antipsychotic Drugs Directly Impair Insulin Action in Adipocytes: Effects on Glucose Transport, Lipogenesis, and Antilipolysis. Neuropsychopharmacol 32, 765–772 (2007). https://doi.org/10.1038/sj.npp.1301142
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301142
Keywords
This article is cited by
-
The anxiolytic drug opipramol inhibits insulin-induced lipogenesis in fat cells and insulin secretion in pancreatic islets
Journal of Physiology and Biochemistry (2023)
-
Antipsychotics impair regulation of glucose metabolism by central glucose
Molecular Psychiatry (2022)
-
Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function—Mechanisms and Possible Therapeutic or Preventive Measures: an Update
Current Obesity Reports (2021)
-
Dopaminergic Pathways in Obesity-Associated Inflammation
Journal of Neuroimmune Pharmacology (2020)
-
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance
Scientific Reports (2019)
